

Swiss HLG Startup Alumni & Community Event

IP Workshop • Alumni Presentations • Networking Apéro



3rd September, 2026
Superlab Suisse, Zürich Schlieren

WE THANK THE SUPPORTERS OF SWISS HLG 2026

Platinum



Gold



Silver



Bronze



WELCOME TO THE SWISS HEALTHCARE LICENSING GROUP

Building relationships for a better healthcare environment

WHO ARE SWISS HLG?

Swiss HLG is an association of Healthcare Executives focusing on Business Development and Partnering with the shared objective to provide a unique and inspiring environment for professional development, sharing best practices and building business relationships.

Swiss HLG is open to the international healthcare and life sciences industries and has over 170 active members, mainly based in Switzerland but also France, Germany, Netherlands, Belgium, Italy, Portugal, Slovenia, China, United Kingdom and United States.

The association is led by a volunteer Board which organizes conferences and delivers key initiatives. We have delivered 36 conferences with an excellent national and international reputation for quality, that offer great opportunities for networking, education, and business development.

Our initiatives aim to bring value to our members and the innovation ecosystem. They include educational webinars, networking events, developing and communicating Good Partnering Practices, a LinkedIn community and the Start-Up Initiative. Please join us!

OUR MISSION

The Swiss HLG is an association of biopharma dealmaking professionals, well recognized within the healthcare industry.

Our goal is to provide a unique and inspiring environment for developing knowledge and skills, sharing best practices and building business relationships.

Here's a brief summary of what membership benefits include:

- Swiss HLG thought leadership and education
- Focused and effective networking with peers
- Attractive discounts for Swiss HLG and partner organisation events and offers
- Opportunity to contribute to our events and the Start-up Initiative
- Dissemination of Good Partnering Practices
- Membership of our private LinkedIn community
- Increased visibility for you and your organization
- Access to the unique IPLS database, encompassing members of an international network of 10 healthcare licensing groups

Visit us at www.swisshlg.com

SWISS HLG START-UP INITIATIVE – GET FIT FOR PARTNERING!

An educational program for early-stage healthcare companies to help them become partnering ready

This complimentary program is offered in collaboration with Johnson & Johnson Innovation and BaseLaunch, and consists of four linked workshops where leading experts will cover essential topics in healthcare business development.

Welcome to our Swiss HLG Startup Alumni Community Event

Dear Members and Friends of the Swiss HLG

It is our pleasure to welcome you to the first community event for Swiss HLG Startup Alumni.

The Swiss HLG has been running the Start-Up Initiative for four years now in close collaboration with Johnson & Johnson and BaseLaunch and with kind support from Venture Valuation and SIX.

Each year we take a cohort of around 30 biotech start-ups from Switzerland and further afield through a linked series of four workshops. These help them to understand how to convey a compelling story that resonates with potential partners and investors, to negotiate a term sheet and to value their assets and company. Feedback has consistently been highly positive.

After successfully completing three years of the program, it is timely to bring this start-up community back together. It's a great chance for them to reconnect, gain some valuable training on the crucial topic of intellectual property, and to present to and network with important guests from biopharma and venture capital.

Our valued supporters HGF are leading an insightful and interactive IP workshop, and we are grateful to Superlab Schlieren for providing us with a great event venue today. We thank you for your participation and support – please enjoy!

With warm regards



Sarah Holland
President
Swiss HLG



Michael Huebner
Board Member
Swiss HLG



Monika Baudler-Klein
Board Member
Swiss HLG



Nathalie Jenni
Board Member
Swiss HLG



Johnson&Johnson **BASELAUNCH**

PROGRAM

Thursday, September 3rd 2026

From 14:00 — Doors Open for External Participants

- 12.00 – 14.00

Private Alumni Networking Lunch
Private lunch for Swiss HLG Startup Alumni. A relaxed space to reconnect, exchange updates, and build new connections before the public program
- From 14:00

Registration and welcome coffee for all attendees joining the afternoon IP Workshop and program
- 14.30 – 16.30

IP Workshop
Neil Henry, Partner at HGF Limited
Frédéric Didelon, Partner at HGF Limited
- 17.00 – 18.30

Alumni Presentations
Showcase of alumni projects, ventures, and success stories.
Includes short Q&A segments
- From – 18.30

Networking Apéro
Informal apéro to continue conversations, meet new participants, and strengthen the community

Optional Superlab tours

- 13.45

We will have three tours of Superlab.
- 16.30

Please sign up and meet outside the main meeting room
- 18.45



BECOME A MEMBER / BECOME A SUPPORTER
WE ARE ONLY AS STRONG AS OUR MEMBERS
www.swisshlg.com



IP WORKSHOP

Abstract

Interactive session led by experts from our valued supporters HGF Limited, focusing on practical IP challenges and real-world case discussions (Open for External Participants)

Synopsis:

Intellectual property is a key driver of value in biotech and start-ups, especially so when it comes to funding, partnerships, and transactions/exits.

The session will highlight:

what IP is;

- why IP matters;
 - what looks 'good' from an IP perspective;
 - what investors look for during IP due diligence; and
 - how to effectively prepare for the IP due diligence process.
- In addition to a refresher of the basics, the session will also provide practical real-world insights & advice on strengthening your IP position, avoiding common pitfalls, and ensuring your innovation is transaction-ready.

Speaker Bios

Neil Henry's patent practice is primarily focused on the pharmaceutical and agrochemical fields. He specialises in drafting and prosecuting patent applications covering new chemical entities, salts/co-crystals, polymorphs, formulations, intermediates, manufacturing processes, medical uses, and non-medical uses.

Neil entered the IP profession in 2007 and spent 17 years as in-house counsel in biotech/biopharma, chemical and agrochemical companies of varying sizes, working across a variety of technology groups and the entire IP and product life cycle.

Neil leverages his in-house experience to provide commercially-minded advice in relation to all patent matters. He has extensive experience in advising on IP strategy, freedom to operate, (in)validity and patentability analyses, in running contentious proceedings, inc. EP opposition & appeal, the negotiation & drafting of IP-related agreements, in due-diligence support of licensing and acquisition deals, supplementary protection certificates/Patent Term Extensions, Loss of Exclusivity assessments, and the strategic use of IP in highly competitive commercial environments.

Frédéric Didelon is a Partner in HGF's Life Sciences team, with more than 25 years of IP experience across the European Patent Office, the pharmaceutical industry and private practice.

He advises pharmaceutical and biotechnology companies on patent strategies supporting research, development, partnering and commercialisation.

Before joining HGF, Frédéric spent nine years as a patent examiner at the European Patent Office, examining pharmaceutical and biotechnology cases, followed by 17 years at Novartis managing global patent portfolios from early research to marketed products. His experience spans patent drafting and prosecution, due diligence, licensing and collaborations across antibodies, gene therapies, antisense technologies and small molecules, with particular expertise in neuroscience. He combines scientific depth, first-hand EPO insight and industry experience with an intimate understanding of how IP informs regulatory exclusivity strategies (loss-of-exclusivity assessments), clinical development (medical-use patent drafting and management) and commercial decision-making (IP portfolio analysis in due diligence, agreement drafting and business forecasting). This enables him to develop pragmatic IP strategies aligned with clients' scientific and commercial objectives.



Neil Henry
Partner
HGF Limited



Frédéric Didelon
Partner
HGF Limited

PROGRAM: ALUMNI PRESENTATIONS

September 3rd, 2026

17.00 – 17.05	Swiss HLG Introduction Sarah Holland, President Swiss HLG
17.05 – 17.10	Superlab introduction
17.10	Alumni Presentations Showcase of alumni projects, ventures, and success stories. Includes short Q&A segments
17.10 – 17.20	Amporin
17.20 – 17.30	BLEEDnFIRE Therapeutics AG
17.30 – 17.40	Barriera Therapeutics (BTX)
17.40 – 17.50	Caldre
17.50 – 18.00	ClearideBio Therapeutics AG
18.00 – 18.10	Iguana BioTechnology GmbH
18.10 – 18.20	Serendip innovations
18.20 – 18.30	Ultimate Medicine
From – 18.30	Networking apero



Abbmira Therapeutics AG

www.abbmira.com

[Presentation Deck](#)

Julia Biwer, COO

julia@abbmira.ch

+41 77 480 32 04

Name of people attending on Sep 3

Dr. Marc Creus, CEO

Julia Biwer, COO

Abbmira Therapeutics is a Basel-based biotech developing innovative medicines that sculpt the innate immune system to recognize and fight cancer more effectively. Our synthetic small molecules are designed to modulate native immune cells for the treatment of NSCLC and Ovarian Cancer, with potential for further indications in oncology and pipeline-expansion towards autoimmune diseases. Our approach is clearly differentiated with a distinct target and mechanism. We appreciate our contacts with pharma experts to understand value-creation better and to guide our R&D development plans. Please get in touch if you want to find out more.



AdveNeuro

<https://adveneuro.com> (under construction)

[Presentation Deck](#)

Matthew Hall - CEO

contact.us@adveneuro.com

Name of people attending on Sep 3

Matthew Hall, CEO

Emilie Dejean, Chief Development Officer

AdveNeuro is a Swiss biotech company pioneering disease-modifying combo therapies in neuroscience, inspired by the success of oncology combo therapies. Its first asset is an in-licensed Phase I-ready CSF1R inhibitor.

Key Advantages:

- First-Mover in disease-modifying neuro combo therapies: targeting a \$25B+ market with unmet needs, adopting proven combo strategies in difficult-to-treat indications (oncology)
- Innovative delivery: intranasal formulation offers a safer CNS-targeted alternative to oral inhibitors
- Regulatory tailwinds: Orphan Drug Designation (ODD) and Fast Track eligibility for multiple indications (e.g., ALS, PSP, FTD)
- Agile organisation: virtual biotech with an expert team overseeing providers/ vendors incl. CDMO and CRO to reduce CAPEX and pharma partners to share clinical study costs and accelerate transfer for late stage development

Current status:

Raising Series A to:

- In-license a Phase I-ready asset (Q4-26), terms agreed upon with Sanofi
- Launch Phase I (H1-28)
- Initiate 2 Phase II combo trials (H1-29) with partners

Goal: build the first disease-modifying combination therapies in CNS, using Phase 2 proof-of-concept readouts to unlock licensing opportunities with mid-to-large-cap pharma.



Alivion AG

www.alivion.ch

Dr. Giorgia Greter

info@alivion.ch

Name of person attending on Sep 3

Dr. Giorgia Greter, Business Development Manager

Alivion is an ETH Zurich spin-off making high-quality chemical analysis accessible beyond the laboratory. Its SmartSelect™ platform combines advanced chemical sensing, molecular selectivity and measurement intelligence to enable precise, molecule-specific measurements directly where they are needed. Alivion partners with industrial companies to integrate these capabilities into their products, equipment and workflows, bringing laboratory-level analytical performance closer to the point of use. Built on more than a decade of ETH Zurich research, SmartSelect has been validated across applications ranging from industrial and food quality control to environmental and health monitoring.



Amporin Pharmaceuticals AG

www.amporin.com

[Presentation Deck](#)

Kelvin Stott – CEO & Cofounder

kelvin.stott@amporin.com

Name of person attending on Sep 3

Kelvin Stott, CEO & Co-founder

Amporin is developing the first class of oral small-molecule drugs designed to target toxic membrane pores formed by misfolded protein oligomers across multiple degenerative diseases, including Alzheimer's, Parkinson's, Type 2 diabetes, and numerous rare disorders. These pores create an ionic short circuit across cell and mitochondrial membranes, driving uncontrolled calcium influx, mitochondrial dysfunction, oxidative stress, and progressive cell death. By protecting and repairing vital cellular membranes, rescuing mitochondria, and restoring function and homeostasis in stressed but still viable cells, we aim to deliver the first oral disease-modifying treatments that slow or halt disease progression while enabling rapid functional recovery across multiple major degenerative diseases, starting with Parkinson's disease.



Ardanza Biopharma AG

www.ardanzabiopharma.com

[Presentation Deck](#)

Jan Werkman, CEO

jan.werkman@ardanzabiopharma.com

Name of person attending on Sep 3

Jan Werkman, CEO

Ardanza Biopharma AG is a Swiss biotechnology company founded in 2024 and headquartered in Zug, Switzerland. The company specializes in identifying and advancing clinical-stage-ready pharmaceutical assets that address significant unmet medical needs. Led by an experienced team with deep expertise in drug development, regulatory affairs, commercialization, and strategic leadership, Ardanza combines scientific innovation with a capital-efficient development model. Its lead asset, ARD-100, is a novel oral therapy for relapsing-remitting multiple sclerosis (RRMS). ARD-100 combines monomethyl fumarate (MMF), a clinically validated MS therapy, with eicosapentaenoic acid (EPA) to create a new molecular entity designed to overcome a key limitation of existing fumarate treatments: gastrointestinal side effects. The product aims to maintain the proven efficacy and safety of the fumarate class while offering improved tolerability and convenient once-daily dosing, supporting better patient adherence and long-term treatment persistence.

Ardanza's business proposition centers on a differentiated, patent-protected therapy with a de-risked and accelerated regulatory pathway, including the FDA 505(b)(2) and EMA hybrid routes.

This strategy has the potential to reduce development timelines, costs, and regulatory risk while accelerating value creation. The ARD-100 development program is supported by leading multiple sclerosis neurologists across Europe and North America, underscoring its scientific and clinical credibility. Projected aggregate sales exceed USD 2.5 billion during the first ten years following commercialization. With the potential to become a best-in-class fumarate and a leading first-line oral therapy for RRMS, Ardanza aims to deliver meaningful benefits for patients and attractive returns for investors.



Atopia Therapeutics

<https://atopiatx.com/>

[Presentation Deck](#)

Gregoire Chevalier, CEO

gchevalier@atopiatx.com

Name of person attending on Sep 3

Gregoire Chevalier, CEO

Atopia Therapeutics is a preclinical-stage biotech in Geneva, Switzerland, developing first-in-class therapies that restore immune tolerance in allergic disease rather than suppress inflammation.

Its lead candidate, ATP-R13, is a first-in-class, orally administered, gut-restricted TGFβR agonist. By acting locally in the intestine without meaningful systemic exposure, ATP-R13 is designed to re-establish tolerance rather than immunosuppression. This distinguishes it from the current standard of care — biologics and JAK inhibitors that require indefinite dosing and carry the safety burden of chronic immunosuppression.

Atopic dermatitis is the lead indication, supported by in vivo proof-of-concept data, with allergic asthma and food allergy as natural expansions of the same mechanism. Atopia is now advancing ATP-R13 through IND-enabling studies.



BLEEDnFIRE Therapeutics AG

<https://bleednfire-tx.com/>

[Presentation Deck](#)

Raja Prince-Eladnani, CSO

r.prince@bleednfire-tx.com

Names of people attending on Sep 3

Raja Prince-Eladnani, CSO

Daan Kok, COO

BLEEDnFIRE Therapeutics is a University of Bern spin-off developing first-in-class RNA medicines for people living with rare bleeding disorders. The company's lead program, BnF-001, is a GalNAc-conjugated small interfering RNA designed to selectively reduce Protein S production in the liver. By partially releasing this natural anticoagulant "brake," BnF-001 aims to restore hemostatic balance without replacing missing clotting factors. The platform is being developed as a single, durable therapy with potential across hemophilia A and B, von Willebrand disease, Glanzmann thrombasthenia, factor XI and VII deficiencies and other rare bleeding disorders. These conditions differ clinically, yet share recurrent bleeding, progressive joint damage, and a high treatment burden. BLEEDnFIRE's ambition is therefore broader than reducing bleed counts: it is to protect joints and bone, simplify prophylaxis, and reduce the constant mental burden associated with bleeding risk.

Preclinical studies have demonstrated consistent Protein S knockdown, restoration of thrombin generation, reduced bleeding, and protection against joint damage across multiple disease models. The underlying therapeutic approach has also been evaluated in non-human primates, supporting its translational potential. The company has secured composition-of-matter and therapeutic-use intellectual property and has raised CHF 3.1 million in non-dilutive funding to advance the program.

Founded with an experienced team spanning clinical and translational hemostasis and hematology, RNA drug development, CMC, operations, finance and drug development strategy, BLEEDnFIRE is working toward clinical entry and a future in which patients can live with greater freedom from bleeding damage. Its guiding vision is simple: free minds from bleeding damage.



Barriera Therapeutics (BTX)

<https://btxbiotech.com>

[Presentation Deck](#)

Tristan Heintz, PhD, Co-founder and CSO

tristan@btxbiotech.com

Names of people attending on Sep 3


Tristan Heintz, PhD, Co-founder and CSO

Joppe Nieuwenhuis, PhD, CEO

Barriera Therapeutics is developing a novel therapy for chronic kidney disease (CKD) designed to preserve kidney barrier function and treat irreversible renal decline with a novel, differentiated mechanism-of-action (MoA). Our lead indication is Alport syndrome, with expansion potential into other rare kidney diseases (TAM = multi \$Bs) and diabetic kidney disease.

In a highly translatable mouse model of Alport syndrome, our treatment demonstrated strong synergy with the standard-of-care ACE inhibitor ramipril, delaying the loss of renal function and substantially extending survival. Treatment increases kidney-cell resilience to the toxicity caused by chronic albumin accumulation, a disease feature shared across multiple kidney disorders. This differentiated mechanism of action provides a clear rationale for expansion into other forms of CKD.

Our target is human-genetically validated in CKD, and is demonstrably druggable. Our chemistry approach offers first-in-class potential with a clear path to strong composition-of-matter IP. The route to proprietary IP has been established and externally confirmed. The team behind BTX consist of second-time founders, experienced in discovery and development of small molecule drugs. BTX is raising a seed round of eur 11M to secure IP, nominate a development candidate within 1.5 years and file for IND within 2.5 years after closing the seed round. This will position BTX for rapid value inflection and expansion into high-value renal indications.



CALDRE

CALDRE AG

<https://www.caldre.ch>

[Presentation Deck](#)

Felix Baier, Co-founder, CEO

felix.baier@caldre.ch

Names of people attending on Sep 3

Felix Baier, Co-founder, CEO

Adrian Keogh, Co-founder, CSO

CALDRE . Cholestasis And Liver Disease Resolved.

CALDRE is a Swiss biotechnology company and University of Bern spin-off developing a first-in-class therapy for cholestatic liver diseases, conditions where toxic bile stagnates and drives progressive liver failure. Patients face chronic fatigue, pain and lost productivity, repeated hospitalisations, and ultimately liver transplantation. Our lead indication, primary sclerosing cholangitis (PSC), has no approved drug.

Our therapy targets Claudin-3, a tight-junction protein of the blood–biliary barrier we identified as a novel target. Targeting Claudin-3 dilutes toxic bile and restores flow, fixing the problem at its source, upstream of inflammation and fibrosis. It is delivered via GalNAc-siRNA, a clinically validated, liver-specific platform behind several approved drugs, enabling infrequent subcutaneous dosing.

We have identified a promising lead candidate with high targeting efficacy, with proof-of-concept validated in animal models. Critically, we have validated our target's expression in patient liver tissue, establishing the human disease link. Our foundational patent protects the target and mechanism. Next steps are further proof-of-concept in long-term models, expansion of the pipeline across other cholestatic indications, and the final work ahead of IND/CTA-enabling studies. The opportunity: a multi-billion-dollar market across PSC and adjacent cholestatic diseases, in a field seeing active pharma M&A. CALDRE has raised predominantly non-dilutive funding and won 1st place at the Swiss Biotech Day 2025. We are currently raising our seed round.



ClearideBio Therapeutics AG

[https://www.clearidebiotx.com/](https://www.clearidebiotx.com/Presentation Deck)

[Presentation Deck](#)

Xiaona Jing, CEO and Co-founder

jing@clearidebio.com

Names of person attending on Sep 3

Xiaona Jing, CEO and Co- founder

ClearideBio Therapeutics is a Basel-based antibody-drug conjugate company building clinically differentiated ADCs for hard-to-treat solid tumors. It is the founders' 4th ADC company; they have taken 8 ADC platforms through clinical translation, and the team comes from NBE-Therapeutics in Basel, acquired by Boehringer Ingelheim for \$1.4 billion.

ClearideBio builds backwards from the end. It is asset-centric and technology-agnostic: every component is selected from the best available innovation and judged on one criterion - its potential to translate in the clinic. Optimization is systematic across all components, with focus on the payload, which is what currently caps the therapeutic window of an ADC.

The lead program, CRB-001, is a bispecific ADC carrying a novel payload engineered for improved PK and safety, directed at squamous NSCLC, colorectal and head and neck cancer. Preclinical candidate and stable cell line are in hand, with the clinic approximately 15 months away.

ClearVeil™ is a payload-masking technology that keeps a payload inert even after the linker is cut and restores it at the tumor. In vivo it delivered more than three times the tolerated dose at matched efficacy, a potentially repeatable payload toolbox, which has been applied across three payload classes. It underpins CRB-002, a dual-payload ADC against a first-in-class target.

The company is funded with a round led by LOTTE CVC and participation from the Lichtsteiner Foundation. The next seed round opens in October.



Evora Biosciences

<https://www.evorabio.com>

Hadrien Lanvin, CEO

hlanvin@evorabio.com

Name of person attending on Sep 3

Hadrien Lanvin, CEO

EVORA BIOSCIENCES is an early stage drug discovery company. The company develops EVO-007 a proprietary anti-inflammatory peptide for topical administration, with ophthalmology and dermatology as lead therapeutic areas.



GliaPharm SA

www.gliapharm.com

Ambroise Magistretti, Co-CEO, Co-founder
amagistretti@gliapharm.com

Name of person attending on Sep 3
Ambroise Magistretti, Co-CEO and Co-founder

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of small molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction. The lead molecule is a first in class for a novel astrocytic based target to correct brain hypometabolism in multiple neurological diseases, including an orphan disease (GLUT1 deficiency syndrome) and Alzheimer's disease. The lead program is IND ready and planned to enter Phase 1.



Iguana BioTechnology GmbH

www.iguana-biotec.com

[Presentation Deck](#)
Volker Wedershoven CEO
vw@iguana-biotec.com

Name of people attending on Sep 3
Dr. Behnam Kalali, CSO
Volker Wedershoven, CEO

Iguana BioTechnology GmbH is a Munich-based biopharmaceutical company developing innovative therapeutic immunotherapies against chronic bacterial infections. Its lead program, ACT21, is a first-in-class, non-antibiotic therapeutic immunotherapy designed to eradicate established *Helicobacter pylori* (H. pylori) infection.

H. pylori infects approximately half of the global population and is classified by the WHO as a Group 1 carcinogen. It is the primary cause of gastric adenocarcinoma. Current eradication therapy relies on combinations of antibiotics, but increasing antimicrobial resistance, declining treatment effectiveness and microbiome disruption create a growing need for effective non-antibiotic alternatives.

ACT21 combines a recombinant fusion protein with an MVA-based viral vector in a heterologous prime-boost regimen. Both components incorporate a proprietary multi-epitope antigen unit comprising 16 conserved B- and T-cell epitopes derived from six essential H. pylori virulence factors, designed to provide broad coverage across genetically diverse strains.

Preclinical development has been completed. ACT21 achieved 100% eradication of established H. pylori infection in a validated therapeutic mouse model, independently reproduced in two laboratories. ACT21-specific antibodies recognized 100% of 48 diverse human clinical isolates. GLP toxicology was completed without adverse findings and with a defined NOAEL.

Following positive scientific advice from the German Paul-Ehrlich-Institut (PEI), ACT21 is ready to advance into GMP manufacturing and Phase I clinical development in H. pylori-positive participants, providing an early clinical efficacy readout alongside safety and tolerability.

Iguana is seeking investors and strategic partners to finance and support ACT21 through Phase I and its defined clinical value inflection.



Inkocell Therapeutics SA

<https://www.inkocell.com/>

[Presentation Deck](#)

Angela Madurga Alonso, CSO and Co-founder

angela.madurgaalonso@inkocell.com

Name of person attending on Sep 3

Angela Madurga Alonso, CSO and Co-founder

CAR-T therapy has transformed the treatment of blood cancers, but it is not readily applicable to T-cell malignancies. Because malignant and healthy T cells share the same surface markers, engineered T cells can attack one another. Moreover, patient-derived cells are often contaminated with malignant T cells, making autologous manufacturing particularly challenging.

For patients with relapsed peripheral T-cell lymphoma, treatment options are extremely limited. Approximately half relapse within one year of chemotherapy, and median survival following relapse is less than six months. This leaves insufficient time to manufacture a personalised cell therapy from the patient's own cells.

Inkocell addresses this challenge using natural killer (NK) cells. NK cells can recognise and eliminate target cells without requiring patient-specific matching, enabling an off-the-shelf product manufactured from healthy donors. A single donor manufacturing run can generate up to 200 doses.

Unlike many CAR-NK approaches that adopt signalling domains from CAR-T cells, Inkocell's platform is designed around NK-cell biology.

The technology has demonstrated superior activity to first-generation CAR-NK cells in vitro and in vivo, while achieving CAR-T-like potency in vitro. The lead candidate further incorporates a persistence module and an inducible safety switch for controlled elimination of the engineered cells. Because CD5 is expressed across multiple T-cell malignancies, this platform also has potential applications beyond peripheral T-cell lymphoma.



InkVivo Technologies SA

<https://www.inkvivo.tech/>

Elia Guzzi

team@inkvivo.tech

Name of person attending on Sep 3

Elia Guzzi

InkVivo Technologies AG is a Swiss biotech company and ETH Zurich spin-off developing a proprietary polymer based platform for drug formulation and delivery. Many promising therapeutic molecules fail to reach patients because of poor bioavailability, unstable release profiles, or delivery routes that limit adherence, a challenge that spans oral and injectable formats alike.

InkVivo addresses this with two platform technologies. The first being GARDS, a gastro retentive oral delivery system, underpins two internal programs: an iron deficiency anemia program now in clinical trials, targeting a condition that affects close to a third of the global population, and a brain health program targeting tauopathies, including Alzheimer's disease, which affects an estimated 55 million people worldwide, currently in preclinical development following encouraging animal model results. The second technology, SHEALD, is an injectable depot system for long acting delivery of biologics, which is supported by preclinical data and extends the platform's reach to large molecule therapeutics. InkVivo integrates a machine learning formulation engine to accelerate formulation design and drug lead optimization, shortening the path from early development into preclinical and clinical stages. InkVivo operates a B2B model, out licensing and co-developing its platform with partners across the pharmaceutical and animal health sectors. This positions the company as an enabling technology partner able to strengthen the delivery profile of existing and new molecules, rather than a single asset developer, broadening its relevance across therapeutic areas and species.

**InterAx Biotech**interaxbiotech.com[Presentation Deck](#)

Andrew Roberts, CEO

roberts@interaxbiotech.com

Name of people attending on Sep 3

Yaroslav Nikolaev, CTO

Aurélien Rizk, CSO

Luca Zenone, CFO&COO

InterAx Biotech is redefining drug discovery by extending conventional optimisation of ligand- and ligand-target chemistry, with optimisation of signaling profiles of drug action. Its proprietary Deep Signal platform decodes how a drug's chemistry drives intracellular signaling, pairing real-time wetlab signaling biology and mechanistic mathematical models with computational chemistry and AI. This lets InterAx optimize the downstream pathways that dictate drug's efficacy and tolerability, thereby accurately predicting drug in vivo behavior long before human trials begin.

The platform is already showing remarkable promise. InterAx is advancing oral small-molecules in metabolism – targeting GLP-1R and GIPR for obesity and type 2 diabetes – alongside with immunology and oncology program targeting ACKR3. Four additional targets are primed for expansion. The preclinical data is highly compelling: the metabolic program shows a 10x potency gain over the leading clinical oral GLP-1, exceptional peptide-like tolerability, and a unique, direct insulin-secretion response not seen in other small molecules. The ACKR3 program shows significant tumor reduction.

The revenue model has two pillars: partnered drug-discovery programs in collaboration with pharma companies, and inhouse pipeline targeting clinical value-inflection points for out-licensing or sale. This dual approach monetizes the technology in the near term while capturing the upside of InterAx's own maturing assets.

By transforming how the industry approaches G protein-coupled receptors, InterAx is positioned to tackle a significant fraction of 400 GPCR targets that currently underpin one-third of all approved drugs – one of the largest and most validated opportunities in modern medicine.

**Limula SA**www.limula.ch[Presentation Deck](#)

Thomas Eaton, CEO

thomas.eaton@limula.ch / info@limula.ch

Name of person attending on Sep 3

Thomas Eaton, CEO

Limula (www.limula.ch) is a Swiss company providing tools for critical hospital infrastructure to make personalised cancer cell therapies scalable and accessible to patients. We offer hospitals a chance to cure patients on site, with a category-defining product combining hardware, single-use consumables and software that delivers all steps of complex production processes in a single instrument. We cut manufacturing costs by half: less labour, less equipment, less complex infrastructure, more lives saved!



Memorises Bio AG

Matthieu Delincé, Chief Scientific Officer
info@memorises.bio

Name of person attending on Sep 3
Matthieu Delincé, Chief Scientific Officer

Nature has engineered powerful antibodies against many diseases. Memorises Bio finds them. Some people control infections or keep cancer in check remarkably well; our Dropzyl® platform captures their antibody repertoires at exceptional depth and converts them into biobank libraries for functional screening. By bringing many more candidates into screening, we improve the chances of identifying antibodies with qualities needed for clinical success. Based in Zurich, Memorises Bio was established in 2026 as a carve-out from Memo Therapeutics following its acquisition by Ipsen. We are backed by life-science investors and validated through pharma partnerships and two platform-derived antibodies have entered clinical development.



Nexilis AG / NX-Spine

<https://www.nexilis.ch>

[Presentation Deck](#)

Leanna Caron, CEO and Board Chairperson
leanna.caron@nexilis.ch

Name of person attending on Sep 3
Leanna Caron, CEO and Board Chairperson

Nexilis / NX-Spine is a Swiss-U.S. development-stage medical technology company advancing its proprietary Immediate Stabilization System (ISS), a platform designed to reinforce compromised cancellous bone before screw placement, improving fixation of orthopedic implants. The company is initially focused on enhancing pedicle screw fixation, with planned expansion into hip, trauma, and other orthopedic applications — large markets with significant unmet clinical need given the increasing prevalence of osteoporosis. The financial implications of screw loosening are significant, driven by readmissions and revision surgery, which together contribute to an annual economic burden of over \$1B in the U.S. alone. No screw design or currently available option addresses the weak-bone problem reliably and safely. Surgeons need a better way to deliver immediate mechanical strength and stability for primary fixation in poor-quality bone without the risks associated with PMMA bone cement, while preserving bone stock, remaining revision-friendly, and working seamlessly with existing pedicle screw systems and hospital, ASC, and bundled-payment workflows. The ISS platform is purpose-built to close that gap.



PDC Therapeutics SA

www.pdcbio.com

[Presentation Deck](#)

Sena Nomak, PhD, Co-Founder & Chief Operating Officer

sena.nomak@pdcbio.com

Name of person attending on Sep 3

Sena Nomak, PhD, Co-Founder & Chief Operating Officer

PDC Therapeutics is a clinical-stage oncology company built around Sagitta®, a targeted delivery platform for polymer-drug conjugates and radiotheranostics. Our aim is to break the efficacy-toxicity trade-off that limits potent anticancer agents: Sagitta turns established drugs, novel payloads and radionuclides into actively targeted, controlled-release nanomedicines with a wider therapeutic window and scalable chemistry.

The platform is clinically validated. Our lead asset RS-0139, an integrin-targeted docetaxel conjugate developed with our parent company RS Research, has completed a multicentre, open-label Phase 1a/1b study in patients with recurrent, locally advanced or metastatic solid tumours, with a positive safety and tolerability profile and an early efficacy signal. The complete Phase 1 dataset has been accepted for the ESMO Congress in Madrid, 23-27 October, its first detailed public disclosure. Behind RS-0139 sits a pipeline built on four platform families, including Sagitta® Radix for radiotheranostics, with programmes from preclinical to clinical stage in high-unmet-need indications. Our founders are Prof. Rana Sanyal, PhD, Chief Scientific Officer and grand prize winner of the European Prize for Women Innovators, and Sena Nomak, PhD, Chief Operating Officer. The group has raised over USD 20M in dilutive and non-dilutive funding to date. We are based at Biopôle in Lausanne and are members of the Swiss Biotech Association and Swiss HLG.

Following the Phase 1 milestone we are running two conversations in parallel: a USD 60M Series B to fund the next stage of clinical development, and partnering discussions - option-to-license, co-development or asset-level - for Sagitta beyond our own pipeline.



Perseo pharma AG

<https://perseo-pharma.com>

[Presentation Deck](#)

Dr. Yves Dudal, CEO

yves.dudal@perseo-pharma.com

Perseo: oral enzyme therapies built for efficacy in the GI tract

The problem and the platform

Enzyme therapies underperform precisely where they act — the gut — because enzymes deactivate quickly, achieve insufficient local exposure, and force heavy pill burdens for limited efficacy across metabolic diseases. The company's platform pairs a protective shield with mucoadhesion so any therapeutic enzyme stays active locally, delivering sustained intestinal activity from a single daily dose. Against standard therapies, it claims high stability, prolonged residence time (>17 hours versus minutes), once-daily low dosing, and a shift from supportive to disease-modifying treatment.

Lead asset and pipeline

PER301 targets exocrine pancreatic insufficiency, a large unmet need despite existing pancreatic enzyme replacement therapy; preclinical data show 33x higher potency than standard of care, potentially replacing 10–20 pills daily with one low-dose pill. Six programs span EPI, PKU, carbohydrate malabsorption, IBD (co-developed), MSUD, and celiac disease, each sharing sustained local activity, no systemic exposure, and scalable development. A shared platform safety package (PER300) accelerates multiple INDs alongside demonstrated manufacturing scalability, stability, and several dosage forms.

Market and ask

Target markets include an established \$1.5bn EPI market, a \$35bn IBD market with no available treatment, and premium-priced rare diseases. Strategy is to advance the lead program to Phase 1b, then partner for late-stage development and commercialization. The company is raising a \$9m Series A, 85% committed, funding IND submission, early clinical proof-of-concept, and pipeline expansion.

Bottom line: a platform-plus-data story with a largely committed round and a clear near-term clinical inflection.

Protein Alternatives SL

www.proteinalternatives.com

[Presentation Deck](#)

Dr Juan Ignacio Imbaud, CEO

info@proteinalternatives.com

+34 91 804 7322

Name of person attending on Sep 3

Dr. Juan Ignacio Imbaud, CEO

Protein Alternatives (ProAlt) is a Spanish biotechnology company developing next-generation precision oncology solutions for metastatic colorectal cancer (mCRC), with a primary focus on innovative antibody therapeutics.

ProAlt's lead therapeutic program is a CDH17-LGR5 bispecific antibody, designed to selectively target colorectal cancer cells by simultaneously addressing two complementary biological features of the disease. By combining CDH17 targeting with LGR5, a marker associated with cancer stem-cell properties and tumor plasticity, the approach aims to address tumor heterogeneity and overcome resistance mechanisms that limit current therapies. ProAlt's strategy is to advance this differentiated antibody program through preclinical development and early clinical validation, creating a high-value asset with significant potential for partnering or licensing.

Complementing its therapeutic pipeline, ProAlt is developing COLOPROOF, a gene expression-based diagnostic for Stage II–III colorectal cancer. COLOPROOF uses a proprietary six-gene signature to stratify patients according to their risk of recurrence and potentially support treatment decision-making. The signature has been evaluated across public datasets comprising more than 1,800 patients and is being further validated using clinical FFPE samples and transcriptomic analyses.

Together, these programs support ProAlt's precision oncology strategy, combining patient stratification with targeted, next-generation antibody therapeutics to address major unmet needs in colorectal cancer.

Quant Biomarkers AG

<https://quantbio.swiss>

[Presentation Deck](#)

Dr. Sanja Tomovska, Founder & CEO

sanja.tomovska@quantbio.swiss

Name of people attending on Sep 3

Dr. Sanja Tomovska, Founder & CEO

Dr. Amela Jusic, Translational Research Lead

Quant Biomarkers AG is a Basel-based Swiss precision diagnostics company developing clinically actionable biomarker solutions across the cardio-kidney-metabolic (CKM) disease spectrum. The company addresses a structural gap: detecting tissue injury early enough to enable timely intervention, rather than waiting for irreversible functional decline.

Its lead innovation, RenoRisk®, is a proprietary multi-pathway urinary biomarker signature designed to detect early kidney injury before conventional measures such as eGFR and UACR indicate significant loss of function. This is particularly relevant in CKM disease, where cardiovascular and metabolic conditions substantially increase kidney damage risk, while chronic kidney disease remains widely underdiagnosed.

RenoRisk® reads several injury pathways at once: extracellular matrix remodelling, coagulation and complement activation. It has demonstrated cross-species and cross-nephropathy conservation in human, animal and paediatric cohorts, with peer-reviewed publications, and is now progressing through adult clinical validation in CKM with leading academic partners CHUV.

The platform serves two markets: pharma and biotech, supporting patient stratification, translational research and clinical trial development; and clinical diagnostics, enabling earlier detection and monitoring of kidney disease. The multianalyte assay runs on standard immunoassay platforms to be used by CROs and central laboratories.

Quant Biomarkers is building a scalable business around biomarker-driven precision medicine, supported by academic and clinical partnerships, senior nephrology expertise, a growing IP portfolio, and CHF 2.5 million secured to date, including non-dilutive funding from Innosuisse (Switzerland) and HSITP (Hong Kong).

Quant Biomarkers is seeking pharma and biotech partners for feasibility collaborations embedding RenoRisk® into CKM development programmes.



RN.AI Therapeutics GmbH

[Presentation Deck](#)

Justin S. Antony, CEO

Justin.antony@rnai-tx.com

Name of person attending on Sep 3

Justin S. Antony, CEO

RN.AI Therapeutics is a Helmholtz spin-off from Prof. Fabian Theis's lab, operational since Q4 2025. The company combines its Cell-to-Target AI platform for Deep Target ID with first-in-class bispecific antibody engineering to address high unmet medical need across immune-mediated inflammatory diseases.

Current Type 2 biologics, including dupilumab and tezepelumab, do not adequately address the multifactorial biology of COPD, atopic dermatitis, and severe asthma.

RN.AI's approach retains a validated Type 2 arm while adding an AI-discovered target addressing Non-Type 2 pathology, aiming to unlock synergistic efficacy for patients unresponsive to T2 biologic therapies.

The lead programme has demonstrated efficacy across six animal models representing COPD, severe asthma, atopic dermatitis, and IPF, specifically addressing Non-T2 pathology. An independent CRO evaluating the data described it as "the first compound showing a beneficial treatment effect in some of the disease models." Freedom to operate has been established, with novel combination IP progressing through filing.

Since incorporation, RN.AI has secured €1.8 million in pre-seed financing and €0.9 million in non-dilutive grant funding. The team has validated 20 bispecific constructs and completed five preclinical efficacy studies across three disease areas.

The founding team comprises Justin S. Antony, Dominik Hartl, Thomas Huber, and Fabian Theis. They bring deep expertise in drug development, respiratory immunology, antibody engineering, computational biology, the Human Cell Atlas, and clinical translation.

RN.AI is raising a €15 million Seed Round, with an optional €10 million extension, to advance its lead programme through IND-enabling studies and into early clinical development.



Selmod GmbH

www.selmod.com

<https://www.linkedin.com/company/42405589>

[Presentation Deck](#)

Frank Gombert, CEO, Pharma Expert

frank.gombert@selmod.com

SElective MODe antimicrobial resistance therapeutics

Selmod performs preclinical research and clinical development of disruptive antifungal and antibacterial therapies needed to address the critical unmet need for the silent pandemic of antimicrobial resistance (AMR).

Our first-in-class drug candidates of new lead structures are active on new targets by new dual mechanisms of action, and active against multi-drug-resistant WHO critical priority pathogens as demonstrated in in-vivo infection proof-of-concept studies.

We offer the opportunity to invest up to 6 million CHF (\$7 million) in our 3 preclinical research assets.

Investments will be made in individual pre-clinical research projects to advance them to the next value-creation milestones: IND ready studies, completion of lead optimization or conclude lead finding.

A Selmod leadership team is a group of highly motivated individuals, focused on developing new therapies for AMR infections, experienced pharma professionals, or expert scientific advisors from Europe and North America.

In the last decade, members have contributed to the approval of 2 new antimicrobials and 2 investigational antimicrobials that have completed phase 3 studies, amongst as well as other clinical candidates in other therapeutic areas.

**Serendip innovations**

<https://serendipinnovations.com/>

[Presentation Deck](#)

Alexandre Hill, Co-founder and CEO

alexandre.hill@serendipinnovations.com

Name of person attending on Sep 3

Alexandre Hill, Co-founder and CEO

Our mission is to unlock the full therapeutic potential of RNA medicines beyond the limitations of conventional lipid nanoparticles (LNPs) delivery and IVT RNA production systems, especially for in vivo cell-therapy developers.

Serendip Innovations is developing a next-generation RNA platform that integrates both RNA manufacturing and targeted delivery beyond the liver. Using a unique plant-based production system and programmable phytovirus-like particles (phytoVLP), we generate functional RNAs directly encapsulated into a proprietary non-viral vector designed for targeted extrahepatic delivery, repeat dosing, and scalable manufacturing. No need to increase dose concentration to reach efficacy, no need to formulate lipids with RNA and cell-targeting ligands.

One platform, one co-development & licensing partnership starting with a simple and fast feasibility study.

**SULFISCON**

<https://www.sulfiscon.ch/en/>

Alexander So, MD. PhD, CEO

alexander.so@sulfiscon.ch

Name of person attending on Sep 3

Alexander So, CEO

SULFISCON is a startup created from the research at the Rheumatology Department of the CHUV in Lausanne. We have designed first-in-class small molecule positive allosteric modulators (PAMs) for the H2S producing enzyme CSE (or CTH or CGL, cystathionine gamma lyase) that augments cellular production of the gasotransmitter H2S. Increased cellular H2S levels have multiple beneficial biological effects.

Our PAMs are active biologically and in vivo in small animal models and exert dose dependent effects on inflammation. We plan to bring the molecules to IND status and commence phase I clinical studies in 2027, to target inflammatory disorders of the skin.

We are looking for investors and/or partners that will bring this to reality. In addition to targeting skin disorders, SULFISCON has a pipeline of other small molecule activators that would be suitable for other clinical indications (in rheumatology and cardiovascular disorders).

The team is composed of the three co-founders: Prof Alexander So (CEO), Dr Sonia Nasi (shareholder) and Prof Nathalie Busso (shareholder), our medicinal chemistry partner is Prof Rainer Riedl (ZHAW) and senior scientist for SULFISCON is Dr Driss Ehrichtiou. SULFISCON has nominated scientific and business advisors (to assist in our development. We have benefited from financial support from INNOSUISSE and the Canton of Vaud (SPEI).



SunRegen Healthcare AG

<https://www.sunregen.ch>

David Guan

david.guan@sunregen.ch

Yuhong Dong

yuhong.dong@sunregen.ch

Name of people attending on Sep 3

David Guan, CEO

Yuhong Dong, CSO, CDO

SunRegen Healthcare AG is a Swiss biopharmaceutical company developing first-in-class therapies for neurodegenerative disorders of the brain and retina. Founded in 2017, the company is advancing SBC003, an oral small molecule with a unique triple mechanism of action — neuroglobin upregulation, lysosomal enhancement, and mitochondrial activation — that both protects and rescues dying neurons.

The science is well validated. In preclinical models, SBC003 showed potent neuroprotective and neuro-restorative efficacy, including rescue of photoreceptors and retinal ganglion cells in non-human primates with optic atrophy. In 2026, SunRegen completed its IND-enabling package, confirming an excellent safety profile with a wide therapeutic window. A tMCAO stroke model further established SBC003 as a lead candidate in acute ischaemic stroke, alongside its potential in retinitis pigmentosa and dry AMD.

In March 2026, the U.S. FDA granted SBC003 Orphan Drug Designation for retinitis pigmentosa — a milestone bringing expedited development pathways and seven years of US market exclusivity upon approval.

20 compassionate-use cases have shown clinical improvement across multiple indications. With 11 granted patents and a clear route into the clinic, SunRegen is positioned to reshape the treatment of neurodegenerative disease. Guided by an experienced leadership team and world-class scientific advisors, we remain focused on delivering therapies to patients with urgent unmet need — and welcome conversations with investors, partners, and clinicians as we move toward first-in-human trials.



SYDRA AG

[tps://sydra.bio](https://sydra.bio)

[Presentation Deck](#)

Dr. Alexander Dakhovnik, CEO / CSO

alex@sydra.bio

SYDRA AG is a Swiss longevity biotechnology company developing small-molecule medicines for age-related diseases.

Unlike conventional AI drug-discovery companies that begin with a predefined biological target, SYDRA uses a phenotype-first “Hit-to-Target” approach. Its proprietary AI identifies and generates novel molecules; whole-organism lifespan assays reveal which compounds affect aging biology; and the strongest hits are subsequently advanced into aged-mouse studies, target deconvolution and mechanism-of-action research in human cells.

SYDRA's AI-native discovery platform combines a proprietary geroprotector-prediction model with DepreSMILER, a 1.7-billion-parameter molecular foundation model developed and trained in-house. The platform has analysed six million compounds, prioritized 63 candidates and produced five statistically significant lifespan-extending hits in *C. elegans*.

Two lead programs, SY23F and SY23H, have progressed through late-life mouse pilot studies and are now advancing toward human-cell target and mechanism-of-action work. A further cohort of AI-generated, drug-like molecular designs is entering synthesis.

SYDRA's objective is to turn lifespan-extending hits into differentiated medicines for age-related diseases and partner these programs with pharmaceutical companies for further development. The company is incorporated in Switzerland and is currently raising a CHF 2.6 million pre-seed round to accelerate its lead programs and expand its proprietary discovery platform.



Talixeon Therapeutics
[Presentation Deck](#)
Dr. Paula Nunes-Hasler
Paula.Nunes@unige.ch

Name of person attending on Sep 3
Dr. Paula Nunes-Hasler, CEO

Talixeon Therapeutics is developing an enhanced tumor-infiltrating lymphocyte (TIL) anticancer therapy using its proprietary ImmuneCell Booster small-molecule technology. TIL therapy can achieve durable responses in aggressive solid tumors after a single treatment, but its wider adoption is constrained by lengthy, costly manufacturing and inconsistent expansion of potent, tumor-reactive T cells. ImmuneCell Boosters strengthen TIL therapy at its weakest point: the quality and efficiency of immune-cell expansion during manufacturing. By acting on antigen-presenting cells, our compounds promote faster growth and stronger activity of tumor-reactive T cells. The small-molecule approach integrates easily into existing workflows and is washed out before infusion. It requires no genetic manipulation, complex cell-selection steps or costly cocktails of biologicals, offering a clear path to improved potency, consistency and speed without major additional cost or regulatory burden. In melanoma patient-derived proof-of-concept studies, our technology improved TIL growth, yield, functional activity, tumor-cell reactivity and tumor-cell killing. All 7 evaluable samples met the predefined activity criteria, while 6/7 met both growth and activity criteria. Our development target is to reduce TIL production time by 30% and double functional potency across multiple tumor types. The program is patent-pending and supported by CHF 900,000 in non-dilutive funding, including an Innosuisse Innovation Project. Talixeon is a pre-incorporation spinout from the University of Geneva, currently advancing in vivo proof-of-concept, with plans to incorporate and raise CHF 3 million in 2027 to establish the company in Switzerland and prepare the technology for clinical validation.



Tandem Therapeutics
<https://tandem-tx.com>
Mamta Chabria, Cofounder & CEO
info@tandem-tx.co

Name of person attending on Sep 3
Mamta Chabria, Co-founder & CEO

Tandem Therapeutics is an ETH Zürich and Paul Scherrer Institute spin-off developing the next generation of disease-modifying antifibrotic therapies through extracellular matrix mechano-targeted peptide-drug conjugates (PDCs). Our proprietary peptides recognize disease-specific mechanical states of the extracellular matrix, transforming the fibrotic microenvironment, long considered a barrier to therapy, into a selective delivery system for targeted treatment. By selectively localizing therapeutic payloads to diseased tissue, we aim to enable potent and safer therapies while minimizing exposure to healthy tissues. Tandem is currently at the preclinical stage, with Progressive Pulmonary Fibrosis (PPF) as its lead program and a pipeline targeting other serious fibrotic diseases. Our approach builds on more than a decade of pioneering research in ECM mechanobiology and peptide engineering, translating fundamental insights into a new therapeutic modality for diseases where current treatments remain limited.



Ultimate Medicine

<https://www.ultimatemedicine.com/>

Belén Fortes

belen.fortes@ultimatemedicine.com

Name of person attending on Sep 3

Antal Szalay, Founder & CEO

Ultimate Medicine is a preclinical biotech pioneering a new class of small molecules that target an elevated, novel toxic metabolite - one that disrupts critical neuronal functions and accelerates disease progression.

UM's lead program is an oral small-molecule inhibitor designed to block synthesis of that metabolite, reducing systemic and brain exposure through the body's natural clearance mechanisms.



Virtuosis Artificial Intelligence SA (Virtuosis AI short name is preferred)

<https://www.virtuosis.ai>

Lara Gervaise, Co-CEO & CSO

lara@virtuosis.ai

Name of person attending on Sep 3

Lara Gervaise, Co-CEO & CSO

Virtuosis AI is an EPFL spin-off developing voice and speech biomarkers for healthcare, with applications across pharmaceutical R&D, clinical trials, patient monitoring, prevention and digital health. From as little as 30 seconds of speech—or passively captured speech during a call—our technology extracts clinically relevant acoustic and linguistic signals without additional hardware or burdensome patient procedures.

Our platform provides scalable, objective and repeatable digital biomarkers across neurological and cognitive conditions such as Alzheimer's disease, mild cognitive impairment, Parkinson's disease, traumatic brain injury (TBI) and ALS; mental health conditions including depression and anxiety; respiratory and pulmonary conditions such as COPD, asthma, tuberculosis and lung cancer; and metabolic conditions including type 2 diabetes and hyperglycemia, alongside broader health-related indicators.

Voice biomarkers can complement traditional clinical assessments by enabling more frequent measurements, detecting subtle changes over time, and supporting patient stratification, treatment-response monitoring and decentralized or hybrid trial designs.

Virtuosis AI combines advanced speech processing and machine learning with explainable, clinically interpretable composite scores and biomarkers. Our technology has already powered more than one million voice checks and is used and evaluated by healthcare organizations internationally, including pharmaceutical and biotech customers, hospitals, universities and insurers.

For pharmaceutical and biotech partners specifically, our technology can support the drug-development lifecycle—from exploratory studies and biomarker discovery to clinical validation, trial endpoints and post-market monitoring.

GOOD PARTNERING PRACTICES

The Good Partnering Practices are a set of principles that provide a best practice framework for Business Development and Licensing. They are presented on the Swiss HLG website as a series of ScENIC chapters in clear and appealing cartoon and booklet formats.

- **S**couting & Prospecting
- **E**valuation & Due Diligence
- **N**egotiation & Execution
- **I**ntegration & Alliance Management
- **C**onflict Resolution & Termination

A shared understanding of commonly accepted principles, terms and processes helps build empathy and trust in the dealmaking environment. This facilitates transparent interactions, avoids misunderstandings, and promotes successful partnerships.

www.swisshlg.com

SCAN THE QR CODE TO VIEW THE GPP BOOKLET



AN INITIATIVE OF SWISS HLG

JOIN US! BE PART OF A CIRCLE OF PASSIONATE, BUSINESS DEVELOPMENT EXECUTIVES.

- Swiss HLG thought leadership and education
- Focused and effective networking with peers
- Attractive discounts for Swiss HLG and partner organisation events and offers
- Opportunity to contribute to our events and the Start-up Initiative
- Dissemination of Good Partnering Practices
- Membership of our private LinkedIn community
- Increased visibility for you and your organization
- Access to the unique IPLS database, encompassing members of an international network of 10 healthcare licensing groups

More info at www.swisshlg.com

SAVE THE DATE

SWISS HLG ROMANDIE NETWORKING EVENT

CARVE-OUTS IN PHARMA AND BEYOND — FROM STRATEGY TO EXECUTION

REGISTER HERE

CAMPUS BIOTECH, GENEVA

THURSDAY, OCTOBER 1, 2026

SWISS HLG BASEL NETWORKING EVENT

MONDAY, NOVEMBER 23, 2026

SWISS HLG ANNUAL FLAGSHIP CONFERENCE 2027

GRAND SUISSE MAJESTIC, MONTREUX



Swiss Healthcare Licensing Group
c/o Grether MacGeorge GmbH
Austrasse 95, 4051 Basel
Switzerland

info@swisshlg.com
www.swisshlg.com